These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 38286420)

  • 1. Design, Synthesis and In Vitro Evaluation of Levodopa Stearic Acid Hydrazide Conjugate for the Management of Parkinson's DiseaseNovel Conjugate for Parkinson's Disease.
    Chinraj V; Reddy RA; Selvaraj J; Sureshkumar R
    Drug Res (Stuttg); 2024 Feb; 74(2):60-66. PubMed ID: 38286420
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuroprotective and neurotoxic roles of levodopa (L-DOPA) in neurodegenerative disorders relating to Parkinson's disease.
    Kostrzewa RM; Kostrzewa JP; Brus R
    Amino Acids; 2002; 23(1-3):57-63. PubMed ID: 12373519
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Are dopamine agonists alternative therapy for levodopa in early stage of Parkinson's disease? No].
    Friedman A
    Neurol Neurochir Pol; 2007; 41(2 Suppl 1):S10-3. PubMed ID: 17941453
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Attenuated dopaminergic neurodegeneration and motor dysfunction in hemiparkinsonian mice lacking the α5 nicotinic acetylcholine receptor subunit.
    Leino S; Koski SK; Hänninen R; Tapanainen T; Rannanpää S; Salminen O
    Neuropharmacology; 2018 Aug; 138():371-380. PubMed ID: 29940207
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LRRK2 BAC transgenic rats develop progressive, L-DOPA-responsive motor impairment, and deficits in dopamine circuit function.
    Sloan M; Alegre-Abarrategui J; Potgieter D; Kaufmann AK; Exley R; Deltheil T; Threlfell S; Connor-Robson N; Brimblecombe K; Wallings R; Cioroch M; Bannerman DM; Bolam JP; Magill PJ; Cragg SJ; Dodson PD; Wade-Martins R
    Hum Mol Genet; 2016 Mar; 25(5):951-63. PubMed ID: 26744332
    [TBL] [Abstract][Full Text] [Related]  

  • 6. L-DOPA: a scapegoat for accelerated neurodegeneration in Parkinson's disease?
    Lipski J; Nistico R; Berretta N; Guatteo E; Bernardi G; Mercuri NB
    Prog Neurobiol; 2011 Sep; 94(4):389-407. PubMed ID: 21723913
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Drug therapy in Parkinson's disease].
    van Hilten JJ; Roos RA
    Ned Tijdschr Geneeskd; 1999 Jan; 143(5):234-40. PubMed ID: 10086151
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liposomal Form of L-Dopa and SH-Sy5y Cell-Derived Exosomes Modulate the Tyrosine Hydroxylase/Dopamine Receptor D2 Signaling Pathway in Parkinson's Rat Models.
    Zarrin P; Dehghani Ashkezari M; Seifati SM
    J Mol Neurosci; 2021 Dec; 71(12):2583-2592. PubMed ID: 34125397
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacodynamic and pharmacokinetic features of cabergoline. Rationale for use in Parkinson's disease.
    Fariello RG
    Drugs; 1998; 55 Suppl 1():10-6. PubMed ID: 9483165
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Levodopa in Parkinson's disease: neurotoxicity issue laid to rest?
    Murer MG; Raisman-Vozari R; Gershanik O
    Drug Saf; 1999 Nov; 21(5):339-52. PubMed ID: 10554050
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bone loss caused by dopaminergic degeneration and levodopa treatment in Parkinson's disease model mice.
    Handa K; Kiyohara S; Yamakawa T; Ishikawa K; Hosonuma M; Sakai N; Karakawa A; Chatani M; Tsuji M; Inagaki K; Kiuchi Y; Takami M; Negishi-Koga T
    Sci Rep; 2019 Sep; 9(1):13768. PubMed ID: 31551490
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mitigating gut microbial degradation of levodopa and enhancing brain dopamine: Implications in Parkinson's disease.
    Cheng G; Hardy M; Hillard CJ; Feix JB; Kalyanaraman B
    Commun Biol; 2024 May; 7(1):668. PubMed ID: 38816577
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic effect of hydrogen sulfide-releasing L-Dopa derivative ACS84 on 6-OHDA-induced Parkinson's disease rat model.
    Xie L; Hu LF; Teo XQ; Tiong CX; Tazzari V; Sparatore A; Del Soldato P; Dawe GS; Bian JS
    PLoS One; 2013; 8(4):e60200. PubMed ID: 23573240
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rethinking Parkinson's disease: could dopamine reduction therapy have clinical utility?
    Sackner-Bernstein J
    J Neurol; 2024 Aug; 271(8):5687-5695. PubMed ID: 38904783
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Short review on dopamine agonists: insight into clinical and research studies relevant to Parkinson's disease.
    Radad K; Gille G; Rausch WD
    Pharmacol Rep; 2005; 57(6):701-12. PubMed ID: 16382188
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Parkinson's Disease: From Pathogenesis to Pharmacogenomics.
    Cacabelos R
    Int J Mol Sci; 2017 Mar; 18(3):. PubMed ID: 28273839
    [TBL] [Abstract][Full Text] [Related]  

  • 17. l-3,4-dihydroxyphenylalanine (l-DOPA) modulates brain iron, dopaminergic neurodegeneration and motor dysfunction in iron overload and mutant alpha-synuclein mouse models of Parkinson's disease.
    Billings JL; Gordon SL; Rawling T; Doble PA; Bush AI; Adlard PA; Finkelstein DI; Hare DJ
    J Neurochem; 2019 Jul; 150(1):88-106. PubMed ID: 30716176
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DopAmide: Novel, Water-Soluble, Slow-Release l-dihydroxyphenylalanine (l-DOPA) Precursor Moderates l-DOPA Conversion to Dopamine and Generates a Sustained Level of Dopamine at Dopaminergic Neurons.
    Atlas D
    CNS Neurosci Ther; 2016 Jun; 22(6):461-7. PubMed ID: 26861609
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reevaluation of levodopa therapy for the treatment of advanced Parkinson's disease.
    Yokochi M
    Parkinsonism Relat Disord; 2009 Jan; 15 Suppl 1():S25-30. PubMed ID: 19131038
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Levodopa enhances synaptic plasticity in the substantia nigra pars reticulata of Parkinson's disease patients.
    Prescott IA; Dostrovsky JO; Moro E; Hodaie M; Lozano AM; Hutchison WD
    Brain; 2009 Feb; 132(Pt 2):309-18. PubMed ID: 19050033
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.